About GENSCRIPT BIO Company

Kingsley Biotechnology Co., Ltd. (the “Company” or “Kingsley”, together with its subsidiaries, the “Group”) is a widely recognized biotechnology company. We have established four main business units, including (i) life sciences services and products business unit; (ii) biologics contract development and production organization (“CDMO”) business unit; (iii) industrial synthetic products business unit; and (iv) comprehensive global cell therapy business unit. The Group achieved strong growth in R&D through commercial delivery for the year ended December 31, 2023 (“current year” and “reporting period”). Since its establishment 21 years ago, the Group has been adhering to the mission of “using biotechnology to make people and nature healthier”. The business needs of our customers are the Group's top priority and the fundamental cornerstone of our long-term development. We have always supported our customers by providing quality, fast delivery, and cost-effective services and products. Internally, we focus on optimizing operational processes and procedures to continuously improve quality and delivery times. Externally, we are actively improving strategic collaboration with business partners aimed at building a healthy biotechnology ecosystem. We hope to make more positive contributions to the biotechnology and biopharmaceutical industry and jointly build the future of the industry. During the reporting period, external revenue from (i) life science services and products, (ii) biologics development services, (iii) industrial synthetic biological products and (iv) cell therapy accounted for approximately 48.2%, 12.7%, 5.1% and 33.9% of the Group's total revenue, respectively. The Group's business operations cover more than 100 countries and regions around the world, with legal entities in the United States (“US”), Hong Kong, Mainland China (“China” or “Mainland China”), Japan, Singapore, the Netherlands, Ireland, the United Kingdom, South Korea, Belgium and Spain. As of December 31, 2023, our professional team comprised approximately 6,937 members. The Group's Life Science Services and Products Division provides a range of services and products, covering customized DNA synthesis, oligonucleotide synthesis, peptide synthesis, protein production, antibody development, and catalog equipment and consumables. By supporting early research and discovery projects in pharmaceutical, biotechnology, and academic institutions, our business makes a significant contribution to the global life science research community. As of December 31, 2023, more than 87,745 international peer-reviewed academic journal articles cited our services and products. Kingsley Booming Biotech is a CDMO division of the Group. Relying on its deep accumulation in various therapeutic fields, Kingsley's Bountiful Biotech provides customers with integrated services from concept to clinical trials to commercialization for macromolecular drug discovery, development and production. Kingsley Boombio has become a leading provider of antibody/protein therapy, cell therapy and gene therapy development companies. Legend Biotechnology Co., Ltd. (“Legendary Bio” or “Legend”) is a subsidiary of the Group dedicated to the treatment and ultimate cure of life-threatening diseases. As a global biotech company, Legend is currently developing a range of advanced cell therapy technology platforms, including autologous and allogeneic chimeric antigen receptor T cells, gammadelta T cells, and natural killer (NK) cell immunotherapy. Legend uses innovative technology at three R&D sites around the world to explore safe, effective, and advanced treatments for patients around the world. Baisjie Biotechnology Co., Ltd. (“Baisjie”) is a subsidiary of the Group. Using its experience in synthetic biology technology, Baisjie engineers proteins and constructs cell factory microbial strains to produce high-quality industrial enzymes and functional proteins, which can be used in feed, alcohol, food, and home care industries. We believe synthetic biology provides us with new technical and commercial opportunities. We have set up a huge direct sales network in over 100 countries and regions around the world. We mainly sell services and products to global customers through our direct sales team, and also sell services and products through independent third party distributors to expand our market share and promote communication with end users. For the year ended December 31, 2023, our sales revenue to customers in the US, mainland China, Europe, Asia Pacific (excluding mainland China) and other regions was approximately USD 506 million, USD 162.5 million, USD 99.5 million, USD 53.2 million and USD 18.3 million, respectively, accounting for approximately 60.2%, 19.4%, 11.9%, 6.3% and 2.2% of our total external earnings, respectively.